This Phase III is evaluating the effectiveness of a targeted therapy (vutrisiran) in people with hereditary transthyretin amyloidosis.
This trial is treating patients with hereditary transthyretin amyloidosis (hATTR amyloidosis).
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
: Participants will receive vutrisiran during the Treatment and Treatment Extension Periods.
Drug: Vutrisiran (ALN-TTRSC02)
: Patisiran will be administered by intravenous (IV) infusion.
Recruiting Hospitals Read More